The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...

Audits of the non-surgical cosmetics industry are under way to check compliance with legislation at both state and federal ...

The CEO, PBR Life Sciences, Ayodeji Alaran in his remarks outlined the critical challenges facing Nigeria’s pharmaceutical ...

Pivoting away from US exposure could help investors to hedge against the possible negative effects of Trump's tariffs.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

As the global trade war deepens, Puerto Rico is seizing the moment to lure international companies to relocate manufacturing ...

More than 100 days into President Donald Trump’s second term, the administration has fallen into a pattern. Trump releases an ...

Christopher Young earns up to $1 million annually as he guts the agency that regulates two of Musk’s biggest companies.

Why India’s foreign policy and India’s Military Doctrine is relevant to the UPSC exam? What is the significance of topics ...

Gov. Gavin Newsom announced today that he will seek to regulate prescription drug middlemen that he blames for driving up ...